BiotechTube

Everolimus (RAD001) , Afinitor®

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neurofibromatosis Type II

Conditions

Neurofibromatosis Type II

Trial Timeline

Oct 1, 2011 → Dec 1, 2013

NCT ID
NCT01419639

About Everolimus (RAD001) , Afinitor®

Everolimus (RAD001) , Afinitor® is a phase 2 stage product being developed by Novartis for Neurofibromatosis Type II. The current trial status is completed. This product is registered under clinical trial identifier NCT01419639. Target conditions include Neurofibromatosis Type II.

What happened to similar drugs?

0 of 1 similar drugs in Neurofibromatosis Type II were approved

Approved (0) Terminated (0) Active (1)
🔄SelumetinibAstraZenecaPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01419639Phase 2Completed

Competing Products

20 competing products in Neurofibromatosis Type II

See all competitors
ProductCompanyStageHype Score
SelumetinibAstraZenecaPhase 2
27
SelumetinibAstraZenecaPhase 1
33
SelumetinibAstraZenecaPhase 1
29
AZD2014AstraZenecaPhase 2
35
Selumetinib + PlaceboAstraZenecaPhase 2
27
Treatment A + Treatment B + Treatment C + Treatment D + AcetaminophenAstraZenecaPhase 1
29
SelumetinibAstraZenecaPhase 1/2
32
SelumetinibAstraZenecaPhase 1
33
Selumetinib granule formulation + Selumetinib capsule formulationAstraZenecaPhase 1/2
36
SelumetinibAstraZenecaPhase 3
44
RAD001: EverolimusNovartisPhase 2
35
RAD001, everolimusNovartisPhase 2
27
TasignaNovartisPhase 1
29
TrametinibNovartisPhase 2
39
Everolimus (RAD001)NovartisPhase 2
27
Sutent®/SunitinibPfizerPhase 2
27
Sorafenib (Nexavar)BayerPhase 2
24
PTC299United TherapeuticsPhase 2
24
REC-2282 + PlaceboRecursion PharmaceuticalsPhase 2/3
24
BinimetinibPacific BiosciencesPhase 2
25